Annelies Cannaert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6536851/publications.pdf

Version: 2024-02-01

34 papers	1,114 citations	430874 18 h-index	414414 32 g-index
35 all docs	35 docs citations	35 times ranked	677 citing authors

#	Article	IF	Citations
1	Machine Learning to Assist in Large-Scale, Activity-Based Synthetic Cannabinoid Receptor Agonist Screening of Serum Samples. Clinical Chemistry, 2022, 68, 906-916.	3.2	5
2	Report on a New Opioid NPS: Chemical and In Vitro Functional Characterization of a Structural Isomer of the MT-45 Derivative Diphenpipenol. Journal of Analytical Toxicology, 2021, 45, 134-140.	2.8	12
3	Shape matters: The application of activityâ€based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drugâ€infused papers seized in prisons. Drug Testing and Analysis, 2021, 13, 628-643.	2.6	28
4	First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?. Journal of Analytical Toxicology, 2021, 44, 937-946.	2.8	31
5	The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pentâ€4en and butâ€3en analogues including MDMBâ€4enâ€PINACA. Drug Testing and Analysis, 2021, 13, 427-438.	2.6	38
6	Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse. Archives of Toxicology, 2021, 95, 489-508.	4.2	20
7	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMBâ€4enâ€PICA, MDMBâ€4enâ€PINACA, ADBâ€4enâ€PINACA, and MMBâ€4CNâ€BUTINACA using a combination of binding and different CB₁ receptor activation assaysâ€”Part II: Structure activity relationship assessment via a Î²â€arrestin recruitment assay. Drug Testing and Analysis, 2021, 13, 1402-1411.	2.6	18
8	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMBâ€4enâ€PICA, MDMBâ€4enâ€PINACA, ADBâ€4enâ€PINACA, and MMBâ€4CNâ€BUTINACA using a combination of binding and different CB₁ receptor activation assays: Part Iâ€”Synthesis, analytical characterization, and binding affinity for human CB₁ receptors. Drug Testing and Analysis, 2021, 13, 1383-1401.	2.6	19
9	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMBâ€4enâ€PICA, MDMBâ€4enâ€PINACA, ADBâ€4enâ€PINACA, and MMBâ€4CNâ€BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Drug Testing and Analysis, 2021, 13, 1412-1429.	2.6	14
10	Are the N â€demethylated metabolites of Uâ€47700 more active than their parent compound? In vitro Î¼â€opioid receptor activation of N â€desmethylâ€Uâ€47700 and N , N â€bisdesmethylâ€Uâ€47700. Drug Testing and Analysis, 2021, , .	2.6	2
11	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience, 2021, 12, 4020-4036.	3.5	7
12	Evidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact. Forensic Toxicology, 2020, 38, 95-107.	2.4	5
13	Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. Drug Testing and Analysis, 2020, 12, 422-430.	2.6	65
14	Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chemical Neuroscience, 2020, 11, 4434-4446.	3.5	62
15	In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Archives of Toxicology, 2020, 94, 3819-3830.	4.2	36
16	In vitro activity profiling of Cumylâ€PEGACLONE variants at the CB₁ receptor: Fluorination versus isomer exploration. Drug Testing and Analysis, 2020, 12, 1336-1343.	2.6	16
17	Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Biochemical Pharmacology, 2020, 177, 113910.	4.4	36
18	In vitro structureâ€“activity relationship determination of 30 psychedelic new psychoactive substances by means of Î²-arrestin 2 recruitment to the serotonin 2A receptor. Archives of Toxicology, 2020, 94, 3449-3460.	4.2	21

#	Article	IF	Citations
19	Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4Â´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine. Archives of Toxicology, 2020, 94, 2009-2025.	4.2	19
20	Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping. Analytical Chemistry, 2020, 92, 6065-6071.	6.5	5
21	Hide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests. Clinical Chemistry, 2019, 65, 1604-1605.	3.2	15
22	Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances. Analytical Chemistry, 2019, 91, 15444-15452.	6.5	16
23	Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples. Frontiers in Chemistry, 2019, 7, 321.	3.6	48
24	Comprehensive investigation on synthetic cannabinoids: Metabolic behavior and potency testing, using 5Fâ€APPâ€PICA and AMBâ€FUBINACA as model compounds. Drug Testing and Analysis, 2019, 11, 1358-1368.	2.6	24
25	Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on Lâ€valine or Lâ€tert â€leucine. Drug Testing and Analysis, 2019, 11, 1183-1191.	2.6	37
26	Activity-based reporter assays for the screening of abused substances in biological matrices. Critical Reviews in Toxicology, 2019, 49, 95-109.	3.9	16
27	Validation of Activity-Based Screening for Synthetic Cannabinoid Receptor Agonists in a Large Set of Serum Samples. Clinical Chemistry, 2019, 65, 347-349.	3.2	13
28	Application of an activityâ€based receptor bioassay to investigate the in vitro activity of selected indoleâ€• and indazoleâ€3â€carboxamideâ€based synthetic cannabinoids at CB1 and CB2 receptors. Drug Testing and Analysis, 2019, 11, 501-511.	2.6	61
29	Molecular dissection of the human A 3 adenosine receptor coupling with Î²-arrestin2. Biochemical Pharmacology, 2018, 148, 298-307.	4.4	34
30	Activity-Based Detection of Cannabinoids in Serum and Plasma Samples. Clinical Chemistry, 2018, 64, 918-926.	3.2	44
31	Activity-Based Concept to Screen Biological Matrices for Opiates and (Synthetic) Opioids. Clinical Chemistry, 2018, 64, 1221-1229.	3.2	46
32	Activity-Based Detection and Bioanalytical Confirmation of a Fatal Carfentanil Intoxication. Frontiers in Pharmacology, 2018, 9, 486.	3.5	27
33	Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System. Analytical Chemistry, 2017, 89, 9527-9536.	6.5	81
34	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. Analytical Chemistry, 2016, 88, 11476-11485.	6.5	193